Literature DB >> 7104149

Haemodynamic effects of metoprolol and pindolol: a comparison in hypertensive patients.

A Svensson, T Gudbrandsson, R Sivertsson, L Hansson.   

Abstract

1 In a double-blind study, 36 patients with essential hypertension were randomly allocated to treatment with either metoprolol, 100--300 mg/day, or pindolol, 5--15 mg/day for 6 months. Haemodynamic investigations were made on three separate occasions. Blood flow in the calves and in the forearm was determined by venous occlusion plethysmography after 6 weeks of placebo, after 6 weeks and again after 6 months of active therapy. 2 Both drugs reduced blood pressure significantly, by 17.1/11.8 mm Hg with metoprolol and 21.9/10.9 mm Hg with pindolol after 6 weeks (P less than 0.005). No further changes were seen after 6 months. 3 Heart rate after 6 weeks was significantly reduced by metoprolol (10.7 +/- 2.4 beats/min, P less than 0.001) but not by pindolol (4.4 +/- 2.3 beats/min, NS). After 6 months a significant reduction was seen also in the pindolol group (5.2 +/- 2.1 beats/min, P less than 0.05). 4 The vascular resistance in the calves at rest was reduced by pindolol (P less than 0.05), whereas resistance tended to increase with metoprolol. 5 Resting vascular resistance in the forearm after 6 months was significantly reduced in the metoprolol group (P less than 0.001) as well as in the pindolol group (P less than 0.02). The increase in forearm vascular resistance seen during leg exercise was not influenced by either drug. 6 Vascular resistance at maximal vasodilatation was unchanged in the calves, but a significant reduction (-17.4 +/- 5.7%, P less than 0.01) in the forearm vascular bed was seen after 6 months of pindolol. No change was observed with metoprolol. 7 It is concluded that pindolol reduces elevated blood pressure partly through peripheral vascular mechanism. Metoprolol, on the other hand, probably acts mainly via central cardiac mechanisms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104149      PMCID: PMC1402178          DOI: 10.1111/j.1365-2125.1982.tb01923.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Experience with pindolol, a betareceptor blocker, in the treatment of hypertension.

Authors:  J H Atterhög; H Dunér; B Pernow
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

2.  Influence of metoprolol and propranolol on hemodynamic effects induced by adrenaline and physical work.

Authors:  G Johnsson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

3.  Comparative hemodynamic studies in man of adrenergic bepta-1-receptors agents without (h 93/26 equal to metoprolol) or with (h 87/07) intrinsic sympathicomimetic activity.

Authors:  J Stenberg; H Wasir; A Amery; R Sannerstedt; L Werkö
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

4.  Effects of adrenaline during treatment with propranolol and metoprolol.

Authors:  C L van Herwaarden; R A Binkhorst; J F Fennis; A van t'Laar
Journal:  Br Med J       Date:  1977-04-16

5.  Hemodynamic effects of acute and prolonged beta-adrenergic blockade in essential hypertension.

Authors:  L Hansson; A J Zweifler; S Julius; S N Hunyor
Journal:  Acta Med Scand       Date:  1974 Jul-Aug

6.  The hemodynamic importance of structural vascular changes in essential hypertension.

Authors:  R Sivertsson
Journal:  Acta Physiol Scand Suppl       Date:  1970

7.  Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations.

Authors:  R C Tarazi; H P Dustan
Journal:  Am J Cardiol       Date:  1972-05       Impact factor: 2.778

8.  The indirect method of recording blood pressure.

Authors:  E B Raftery; A P Ward
Journal:  Cardiovasc Res       Date:  1968-04       Impact factor: 10.787

9.  Differentiation of receptors responsive to isoproterenol.

Authors:  A M Lands; F P Luduena; H J Buzzo
Journal:  Life Sci       Date:  1967-11-01       Impact factor: 5.037

10.  Comparative chronotropic activity of beta-adrenoceptive antagonists.

Authors:  A M Barrett; J Carter
Journal:  Br J Pharmacol       Date:  1970-11       Impact factor: 8.739

View more
  8 in total

1.  Exercise haemodynamic effects of beta-blockade and intrinsic sympathomimetic activity.

Authors:  P A Ades; E E Wolfel; W R Hiatt; C Fee; R Rolfs; H L Brammell; L D Horwitz
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  ISA--vasodilatation: improvement of organ perfusion.

Authors:  L Hansson
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

Review 3.  Systemic and regional haemodynamic profile of diuretics and alpha- and beta-blockers. A review comparing acute and chronic effects.

Authors:  A Mimran; G Ducailar
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Changes to the vascular system resulting from hypertension and their effects on response to therapy.

Authors:  M J Mulvany
Journal:  Drugs       Date:  1990       Impact factor: 9.546

5.  Acute and long-term antihypertensive effect of bopindolol--a nonselective beta-adrenergic blocker with ISA.

Authors:  O K Andersson; T Hedner; G Nyberg
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Peripheral vascular effects of bufuralol in hypertensive and normal subjects: a comparison with propranolol and pindolol.

Authors:  G D Johnston; M B Finch; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients.

Authors:  B Dahlöf; M Danielson; O Andersson; T Thulin; P Ohman; C Mörlin; J Boberg; B E Karlberg; S Jern; L Hansson
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

8.  Changes in the haemodynamics of large arteries induced by single doses of nicardipine, enalapril, atenolol and urapidil.

Authors:  P Pancera; E Arosio; F Priante; M Ribul; M Zannoni; G Talamini; A Lechi
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.